EVH:NYSEEvolent Health, Inc Analysis
Data as of 2026-09-20 - not real-time
$3.69
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Evolent Health, Inc. is neutral at $3.69, with no clear ordering between short and long averages. Over a rolling month the price has gained 2.8%. RSI sits at 32.5, which reads as approaching oversold, and MACD momentum is bearish. Recent trading has carved out support near $3.62 and resistance around $5.03.
The shares look undervalued, trading on 9.4 times earnings below a sector average of 30.1. Consensus targets land 56.3% above where the shares trade now. Revenue is growing at 46.9% on a -24.1% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 65.2%, a beta of 0.93 and a maximum drawdown of 77.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The shares look undervalued, trading on 9.4 times earnings below a sector average of 30.1. Consensus targets land 56.3% above where the shares trade now. Revenue is growing at 46.9% on a -24.1% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 65.2%, a beta of 0.93 and a maximum drawdown of 77.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top Market Events
Healthcare solutions company Evolent Health NYSE:EVH reported Q2 CY2026 results , with sales up 46.Evolent Health Inc EVH delivers robust Q2 2026 results with record revenue and EBITDA, while navigating Medicaid...Healthcare solutions company Evolent Health NYSE:EVH missed Wall Street’s revenue expectations in Q1 CY2026 as sales...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 3.85
- MACD momentum is negative
- 30-day volatility of 65.2%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 9.4 versus sector average of 30.1
- Trading below the 200-day average of 3.85
- Analyst targets imply +56.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 9.4 versus sector average of 30.1
- Negative profit margin of -24.1%
- Analyst targets imply +56.3% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth46.90%
Profit Margin-24.08%
P/E Ratio9.4
ROE-66.97%
ROA-0.79%
Debt/Equity253.23
P/B Ratio1.1
Op. Cash Flow$54.3M
Free Cash Flow$184.3M
Industry P/E30.1
Technical Analysis
TrendNeutral
RSI32.5
Support$3.63
Resistance$5.03
MA 20$4.29
MA 50$4.42
MA 200$3.85
MACDBearish
VolumeIncreasing
Fear & Greed Index94.98
Valuation
Fair Value$47.29
Target Price$5.77
Upside/Downside56.35%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.93
Volatility65.23%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.